Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Public Health Emergency: SOLIDARITY TRIAL Philippines
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- University of the Philippines
- Target Recruit Count
- 1314
- Registration Number
- NCT05024006
- Locations
- 🇵🇭
Chinese General Hospital, Manila, Metro Manila, Philippines
🇵🇭UP - Philippine General Hospital, Manila, Metro Manila, Philippines
🇵🇭San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines
Efficacy and Safety of Baricitinib in Sjogren's Syndrome
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05016297
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Health Institutes of Turkey
- Target Recruit Count
- 1120
- Registration Number
- NCT04981379
- Locations
- 🇹🇷
Ankara City Hospital, Ankara, Turkey
🇹🇷Istanbul University Istanbul Medicine Faculty, Istanbul, Turkey
🇹🇷Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, Istanbul, Turkey
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT04973566
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
The Clinical Features and Pregnancy Outcomes of CTD Patients
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 126
- Registration Number
- NCT04918524
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 40
- Registration Number
- NCT04911816
- Locations
- 🇺🇸
West Virginia University Cancer Institute Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- October 6 University
- Target Recruit Count
- 150
- Registration Number
- NCT04779047
- Locations
- 🇪🇬
Beni-suef University, Banī Suwayf, Egypt
Hydroxychloroquine in Prevention of Preeclampsia
- Conditions
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 50
- Registration Number
- NCT04755322
- Locations
- 🇪🇬
Abdel-rahman Mahmoud Mohammed, Assiut, Egypt
Ivermectin Role in Covid-19 Clinical Trial
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Elaraby Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT04746365
- Locations
- 🇪🇬
Shebin-Elkom teaching hospital, Shibīn Al Kawm, Menoufia, Egypt
Montelukast - a Treatment Choice for COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- University of Sargodha
- Target Recruit Count
- 150
- Registration Number
- NCT04714515
- Locations
- 🇨🇳
Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China, Shanghai, China
🇵🇰Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan, Lahore, Punjab, Pakistan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.